Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report

Fabry disease is a rare genetic disease caused by a deficiency of α-galactosidase A gene (α-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.

Agalsidaz beta sonrasý anafilaksi geliþen Fabry hastalýðý olan bir hastanýn agalsidaz alfa ile baþarýlý tedavisi: Olgu sunumu

Fabry hastalýðý, α-galaktosidaz A genindeki (α-Gal A) bir patolojiden kaynaklanan nadir bir genetik hastalýktýr. Ýki haftada bir uygulanan iki intravenöz enzim, agalsidaz alfa ve beta, organ hasarýndan önce erken uygulandýklarýnda, hastalýðýn ilerlemesini yavaþlatabilir ve saðkalýmý arttýrabilir. Bu vaka raporunda, agalsidaz alfa ile baþarýlý bir þekilde tedavi edilen ve agalsidaz beta ile anafilaksi öyküsü olan bir hastayý sunuyoruz. (NCI-2022-6-24/R1)